
Secukinumab Use in Refractory Giant Cell Arteritis
In 2023, the phase 2 TitAIN study showed that the effectiveness and safety of secukinumab in 52 patients with giant cell arteritis (GCA) who had an inadequate response to tocilizumab. While we await the results of a larger https://t.co/HkMT9QEMg8
Dr. John Cush @RheumNow( View Tweet )

Sometimes you hear:
“PMR dose steroids don’t really matter”
Errrrr…
(You wouldn’t accept this steroid exposure in any other disease. Never)
#EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj
David Liew @drdavidliew( View Tweet )

Management of SLE:
-Treat early to prevent organ damage
-Taper GC to <5mg/d in the first 6m when feasible
-New therapies are promising but still unmet needs in LN, limited global access and lacking data in pregnancy.
#EULAR2025 @RheumNow https://t.co/UKK8sTYJD2
Links:
Adela Castro @AdelaCastro222( View Tweet )

-Difficult to treat RA is a heterogeneous concept
-Risk fx: younger onset, high disease activity,erosive disease, comorbidities, depression.
-Study in a Spanish cohort with D2T 2/2 inefficacy showed Rituximab, JAKis, and IL-6i had longer survival (hence better tx options).
-The https://t.co/ZCZcX9FRfb
Adela Castro @AdelaCastro222( View Tweet )

#EULAR2025 Abstr#OP0041 FcRn-inhibition is showing consistency in #Sjogren. Last year it was Nipocalimab. This proof-of-concept study showed efgartigimod met its primary endpoint, the CRESS response. No difference in ESSPRI. Phase 3 UNITY is underway @RheumNow https://t.co/jw1i4FqkIh
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR2025 Abstr#OP0035 SGLT2-i and GLP-1 agonist are increasingly used to treat diabetes. Population based study in Canada showed no significant difference in risk of developing an autoimmune rheumatic disease with GLP-1-RA or SGLT2i relative to DPP4i treatment @RheumNow https://t.co/CvPcOqehtl
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

#Enpatoran a #TLRi in Phase2 #SLE #RCT
-previous data + small #cutaneous #lupus study
various doses &PBO approx 25/group
Interesting data - seems to ⬇️#IFN
+ endpoints
👀 for more to come! Safe so far
#EULAR2025 @RheumNow @eular_org LateBreaking I https://t.co/OtgiasBerX
Links:
Janet Pope @Janetbirdope( View Tweet )

FMF #Recommendations
#Colchicine can be fatal
🔺️Beware of drug interactions
🔺️Mostly statins in adults
🔺️Macrolides in children
#EULAR2025
@RheumNow https://t.co/SYGLpAJXFu
Nelly ZIADE 🍀 @Nellziade( View Tweet )

@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains.
Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for
#EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
Links:
David Liew @drdavidliew( View Tweet )

Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA:
✅ ACR20: 54% vs 34% (placebo)
✅ Skin, joints, fatigue, QoL
📉 Post hoc: less radiographic progression
No new safety signals at W16.
LB0001 @RheumNow #EULAR2025
Jiha Lee @JihaRheum( View Tweet )

from Rituximab to BiTES to CAR T, always looking for deeper B cell depletion
Safety data from CC312 CD19/CD3/CD28, a triple engager in refractory moderate-to-severe SLE
So far so good but how far do we need to go?
#EULAR2025 @RheumNow LB0007
Aurelie Najm @AurelieRheumo( View Tweet )

#EULAR2025 Abstr#LB0001 Phase 3 RCT of Deucravacitinib in psoriatic arthritis met endpoints (ACR20) over PBO at Week 16. Prespecified early radiographic was not significant but post-hoc (without imputed data) showed radiographic inhibition @RheumNow https://t.co/ORUBtUWH31
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID).
Acceptable safety profile & tolerability.
@RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n
Mrinalini Dey @DrMiniDey( View Tweet )

🌳#WILLOW: TLR7/8 inhibition with enpatoran led to greater BICLA response, IFN signature reduction & skin improvement (CLASI-50/70) in active SLE vs placebo at 24wks. Most benefit seen in pts with high IFN-GS or GC use. Good tolerability.
@RheumNow #EULAR2025 #LB0004
Mrinalini Dey @DrMiniDey( View Tweet )

Leaky pipeline in rheumatology:
In a 23-country survey, women left hospital practice earlier—26% at trainee level vs 7% of men.
Top reasons?
🚫 Unfair promotion
🚫 Poor communication
🚫 No career path
Workplace equity still lags.
POS0407 @RheumNow #EULAR2025
Jiha Lee @JihaRheum( View Tweet )

Nerandomilast: the new & improved nintedanib.
Does it work for our rheum pts?
Autoimmune subgroup of FIBRONEER-ILD (NEJM last month)
- mortality benefit vs placebo (this is new)
- well tolerated (minimal increase in diarrhoea vs placebo)
One to watch
#EULAR2025 LB0003 @RheumNow https://t.co/u8fIy7kkKW
Links:
David Liew @drdavidliew( View Tweet )

FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast
1100+ pts, 320+ w/ SARD-ILD wk52
FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO
HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group
11% https://t.co/CeXWB2GlOe
Aurelie Najm @AurelieRheumo( View Tweet )

#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Guselkumab in APEX study (PsA, n=1020, biologic-naïve):
🦴 Less joint damage: 0.55 vs 1.35 (placebo)
💪 More responders: 67–68% hit ACR20 on GUS
🛡 Safety: similar to placebo
GUS - selective IL-23i - delivers joint protection and symptom relief
LB0010 @RheumNow #EULAR2025
Jiha Lee @JihaRheum( View Tweet )

In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS.
Remission matters for subsequent Tx reduction.
@RheumNow #EULAR2025 #LB0006
Mrinalini Dey @DrMiniDey( View Tweet )

#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )

Enpatoran (TLR7/8 inhibitor) in SLE & CLE
- helps skin, others?
- suppresses interferon
lowest dose was highest response though (upsetting primary endpoint)
Promising, watch for the ph3
No photos allowed, but official slides:
https://t.co/1yX6XrYvKH
#EULAR2025 LB0004 @RheumNow
David Liew @drdavidliew( View Tweet )

💉Early results from a dose-escalation trial of novel CD19xCD3xCD28 trispecific antibody (CC312) in refractory #SLE show no ICANS or ≥G2 CRS, rapid B cell depletion & 100% SRI-4 response (n=5).
@RheumNow #EULAR2025 #LB0007 #CART
Mrinalini Dey @DrMiniDey( View Tweet )